Fierce Pharma
NOVEMBER 30, 2023
With layoffs hitting employees on both sides of the Atlantic, Pfizer’s $3.5 billion cost-cutting spree has kicked it into high gear this month. | The company's Groton, Connecticut, research site is the latest to fall victim to job cuts as part of Pfizer's massive $3.5 billion cost-cutting mission, following layoffs across the U.S. and the U.K.
MedCity News
NOVEMBER 30, 2023
While more generative AI tools are becoming available in healthcare for diagnostics and patient communication, it is important for clinicians and healthcare staff to be aware of the security, privacy, and compliance risks when entering protected health information (PHI) into a tool like ChatGPT.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
NOVEMBER 30, 2023
The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal. | The sizzling antibody-drug conjugate field is at the center of another major life sciences deal. Hoping to redeem itself following the epic Rova-T failure, AbbVie is shelling out $10.1 billion in cash to acquire ImmunoGen, maker of the ovarian cancer treatment Elahere.
MedCity News
NOVEMBER 30, 2023
With Cigna mostly focused on the commercial market and Humana mostly focused on the Medicare Advantage market, the rumored combination rumors check out, according to one industry expert.
Fierce Pharma
NOVEMBER 30, 2023
Way back in 2015 a post on the Think with Google blog made the bold claim that, for marketers, consumer intent is more powerful than demographics: “Intent beats identity. | GoodRx is a trusted, high-intent platform that helps providers and patients find what they need at the exact moment they are looking for something. Learn why intent matters more than demographics.
MedCity News
NOVEMBER 30, 2023
By revisiting practice workflows to implement more strategic habits of communication and documentation, clinicians can promote positive outcomes and mitigate practice liability risks at a time when patients maybe accessing care from myriad sources, some online.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
NOVEMBER 30, 2023
Alpha Sophia Founder and CEO Paul-Lukas Hoffschmidt explains how the company’s software diverges from competitors in healthcare commercial intelligence, by focusing on smaller medtech innovators.
Fierce Pharma
NOVEMBER 30, 2023
Seven weeks after a federal judge dismissed (PDF) a Novo Nordisk’s lawsuit, which accu | Seven weeks after a federal judge dismissed a Novo Nordisk’s lawsuit, which accused a Florida pharmacy of selling unauthorized knockoffs of its GLP-1 Wegovy, Ozempic and Rybelsus, Novo has sued the same company. Brooksville Pharmaceuticals is the target of a refiled Novo lawsuit, this one claiming there are impurities in the company’s compounded versions of the popular weight loss treatments.
MedCity News
NOVEMBER 30, 2023
AbbVie announced plans to acquire Immunogen — and the biotech’s recently approved ADC treatment for ovarian cancer — for $10.1 billion in cash. The pharma giant is diving into ADCs again after a previous multibillion-dollar acquisition of a different ADC drugmaker ended up failing a few years ago.
Fierce Pharma
NOVEMBER 30, 2023
As the battle between new respiratory syncytial virus (RSV) vaccines heats up, GSK is “delighted” with the progress it's made so far with Arexvy, the company's CEO Emma Walmsley has said. | As the battle between new respiratory syncytial virus vaccines heats up, GSK is “delighted” with the progress it's made so far with Arexvy, the company’s CEO Emma Walmsley said during a Reuters interview.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
NOVEMBER 30, 2023
The Walgreens Rx Savings Finder combines different third-party discount card options into one platform. It allows customers to search for a prescription, find a coupon for that prescription and text or email the coupon to themselves. They then show the coupon to a Walgreens pharmacist when they fill the prescription.
Fierce Pharma
NOVEMBER 30, 2023
Because of the recent Thanksgiving holiday in the U.S., we're highlighting two weeks' worth of biopharma news related to Asia. | AstraZeneca in-licensed a KRAS G12D inhibitor from China's Usynova. BeiGene bought global rights to a CDK2 inhibitor in a deal worth up to $1.3 billion. Coherus has priced the first Chinese PD-1 inhibitor to enter the U.S. market at a 20% discount to Merck's Keytruda.
pharmaphorum
NOVEMBER 30, 2023
AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.
Fierce Pharma
NOVEMBER 30, 2023
It’s critical to keep your workplace equipment clean and calibrated—especially in the realm of pharmaceutical manufacturing. Now, Dr. | It’s critical to keep your workplace equipment clean and calibrated—especially in the realm of pharmaceutical manufacturing. Now, Dr. Reddy’s failure to uphold those standards has landed the Indian drugmaker in hot water with the U.S.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PharmaVoice
NOVEMBER 30, 2023
John Mulligan, founder of biotechs like Good Therapeutics and Bonum Therapeutics, discusses how biotechs can thrive when the market is against them.
Fierce Pharma
NOVEMBER 30, 2023
Did you know nearly 1.3 million cases of blood cancer are diagnosed worldwide each year?1 | An inside look at Sanofi’s approach to hematology R&D: Q&A with new Global Head of Oncology, Olivier Nataf.
European Pharmaceutical Review
NOVEMBER 30, 2023
Biocon Biologics Ltd has successfully completed integration of Viatris’ biosimilar business in 31 European countries. Following the acquisition of substantially all global biosimilar business of Viatris in November 2022, and the related integration of over 70 emerging market countries in July 2023 and North America in September 2023, now that Viatris’ biosimilars operations have fully transitioned to Biocon Biologics Ltd in Europe, the company declared that this “represents another significant m
Fierce Pharma
NOVEMBER 30, 2023
Written by: Philippe Michiels, Principal Architect at Datapharm | Datapharm presents the case for standardizing digital formats of medicines information, which for too long has been characterized by unstructured data.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
pharmaphorum
NOVEMBER 30, 2023
FDA chief scientist Namandjé Bumpus has been named as principal deputy commissioner, replacing long-serving Janet Woodcock when she steps down early next year. Bumpus is heading for the number two position at the FDA – second only to Commissioner Robert Califf who announced the appointment on X (formerly Twitter) – just over a year after she joined the agency.
Fierce Pharma
NOVEMBER 30, 2023
As Johnson & Johnson’s top moneymaker Stelara nears its patent cliff, biosimilar makers are eager to launch their own versions of the blockbuster immunology med. | Samsung Bioepis' biosimilar, which Sandoz has agreed to commercialize, can launch on Feb. 22, 2025, pending an FDA approval. J&J has reached similar deals with other companies seeking to market their own Stelara biosimilars.
European Pharmaceutical Review
NOVEMBER 30, 2023
In a paper published in Microbiology Spectrum , researchers from Singapore have described a novel microbial contamination-detection method for T-cell cultures that can be achieved within 24 hours, therefore supporting cell therapy manufacturing. This is compared to traditional methods which take between seven to 14 days. Technology such as third-generation nanopore long-read sequencing and DNA extraction, alongside machine learning algorithms, computational analysis and optimisation, were utili
PharmExec
NOVEMBER 30, 2023
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but serious and potentially fatal reaction linked to use of antiseizure medications.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
NOVEMBER 30, 2023
The move is a strategic response amid challenges faced by the non-viral gene therapy sector, with several startups closing this year.
European Pharmaceutical Review
NOVEMBER 30, 2023
o find out about the current trends in cell and gene therapy manufacturing, EPR spoke to Cell and Gene Therapy Catapult (CGT Catapult)’s Chief Manufacturing Officer, Stephen Ward, and Chief Business Officer, Jeanette Evans. They highlighted key data from the organisations recently published good manufacturing practice (GMP) Manufacturing Survey and Skills Demand reports, which focus particularly on the UK’s landscape.
Pharmaceutical Technology
NOVEMBER 30, 2023
As more cell and gene therapies get approved to treat common conditions, scaling them up will be a challenge.
MedCity News
NOVEMBER 30, 2023
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
PharmaTimes
NOVEMBER 30, 2023
The new hub will unite researchers worldwide to exchange ideas and knowledge - News - PharmaTimes
PharmExec
NOVEMBER 30, 2023
The use of real-world evidence can prevent pharma companies from performing studies based on flawed data.
Pharmaceutical Technology
NOVEMBER 30, 2023
GlobalData tracks 49 drugs in development for Gliosarcoma by 39 companies/universities/institutes. The top development phase for Gliosarcoma is phase i, with 22 drugs in that stage.
PharmaTimes
NOVEMBER 30, 2023
The new method successfully performs sterility assessments within 24 hours - News - PharmaTimes
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
362 
Let's personalize your content